SOUTH JORDAN, Utah, July 25, 2018 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) (“Merit”), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and
therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy, today announced the pricing
of its underwritten public offering of 3,500,000 shares of common stock at a price of $54.00 per share (before underwriting
discounts). In addition, Merit has granted the underwriters participating in the offering a 30-day option to buy up to an
additional 525,000 shares of common stock at the public offering price, less underwriting discounts. The offering is expected to
close on or about July 30, 2018, subject to customary closing conditions.
Merit expects to use the net proceeds from the offering to repay debt under its existing credit facility.
Wells Fargo Securities and Piper Jaffray & Co. are acting as joint bookrunners and representatives of the
underwriters for the offering. Canaccord Genuity, Raymond James, SunTrust Robinson Humphrey, Barrington Research and Sidoti &
Company, LLC are acting as co-managers.
Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available,
free of charge on the Securities and Exchange Commission’s website at www.sec.gov or by sending a request
to (a) Wells Fargo Securities, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York, 10152, at (800)
326-5897 or email a request to cmclientsupport@wellsfargo.com, or (b) Piper Jaffray & Co., Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn: Prospectus Department (or by e-mail at prospectus@pjc.com or telephone at (800) 747-3924).
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities
described herein, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
The securities discussed herein will be offered and sold pursuant to an effective shelf registration statement on Form S-3
previously filed with the Securities and Exchange Commission, and the offering will be made only by means of a prospectus
supplement and accompanying prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the
“Securities Act”).
ABOUT MERIT
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of
proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology,
radiology, oncology, critical care and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales
force and clinical support team totaling in excess of 300 individuals. Merit employs approximately 5,400 people worldwide with
facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose,
California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville,
Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; and Singapore.
FORWARD-LOOKING STATEMENTS
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities
Act, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be
identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,”
“estimates,” “potential,” “forecasts,” “continue,” or other forms of these words or similar words or expressions, or the negative
thereof or other comparable terminology. Forward-looking statements in this release include statements regarding the proposed
public offering of shares of common stock and the anticipated use of the net proceeds therefrom, and are subject to a number of
risks and uncertainties that may cause actual results or outcomes to be materially different from those expressed or implied by the
forward-looking statements. These risks and uncertainties include risks relating to the sufficiency of demand for Merit’s common
stock, the price Merit is able to obtain for Merit’s common stock and satisfaction of customary closing conditions for the offering
for an underwritten offering of securities, as well as the risks and uncertainties that could affect Merit’s business and financial
results described in the preliminary prospectus supplement and accompanying prospectus referenced above (as well as Merit’s other
filings with the SEC and incorporated by reference therein, including under the caption “Risk Factors” in Merit’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2017). Forward-looking statements relate only to events as of the date on which
the statements are made and actual results or events may differ materially from anticipated results or events. Except as required
by law, Merit undertakes no obligation to update or revise any forward-looking statements, even if subsequent events cause its
views to change.
Contact: Anne-Marie Wright, Vice President,
Corporate Communications
Phone: (801) 208-4167 e-mail: awright@merit.com Fax: (801) 253-1688
